$0.10
0.00%
Nasdaq, Sep 28, 04:00 pm EDT.
ISIN
BSP733981026
Symbol
NYMXF

Nymox Pharmaceutical Corp Stock price

$0.10
+0.10 49,900.00% 1M
+0.03 41.84% 6M
+0.06 148.76% YTD
+0.05 119.78% 1Y
-0.43 80.95% 3Y
-1.91 95.02% 5Y
-3.13 96.90% 10Y
-3.65 97.33% 20Y
Nasdaq, Closing price Tue, Sep 29 2026
+0.00 0.00%
ISIN
BSP733981026
Symbol
NYMXF
Industry

Is Nymox Pharmaceutical Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$10.5m
Enterprise Value
$10.4m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-1,035.9%
Return on Equity
66.3%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
4.7%
Employees
18
Rev per Employee
$0.0

Financial data from Nymox Pharmaceutical Corp

Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 0.31 0.31
93% 93%
-
- Research and Development Expense 1.14 1.14
71% 71%
-
-1.44 -1.44
83% 83%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -1.44 -1.44
83% 83%
-
Net Profit -1.57 -1.57
82% 82%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nymox Pharmaceutical Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nymox Pharmaceutical Corp Stock News

Neutral
Accesswire
●
3 months ago
IRVINE, CA / ACCESS Newswire / June 17, 2026 / Nymox Pharmaceutical Corporation ("Nymox", "The Company") (OTCQB:NYMXF) is pleased to announce that it has entered into a formal agreement for its drug treatments for prostate conditions, with the Global Alliance of Regenerative Medicine (GARM) on Roatan Island in the Western Caribbean. Nymox's Nymozarfex (TM) which is owned and developed by Nymox,...
Neutral
Accesswire
●
4 months ago
IRVINE, CA / ACCESS Newswire / June 2, 2026 / Nymox Pharmaceutical Corporation ("Nymox", "The Company") (OTCQB:NYMXF) reports that its plans for Nymozarfex (TM) are currently focused on re-submission in the US for marketing approval. The initial US submission was not accepted to be reviewed.

Company Profile

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

Head office Bahamas
CEO Dr. Averback
Employees 18
Founded 1995
Website nymox.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today